

Active substances set

Search phrase: enzalutamide

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant prostate cancer

Enzalutamide

Enzalutamide is indicated for: - the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. - the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). - the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. - the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO